# Zydus receives approvals from the USFDA for Albendazole Tablets and Pregabalin Capsules

*Ahmedabad, 15 December, 2018*

Zydus Cadila has received the final approval from the USFDA to market Albendazole Tablets USP (US RLD – ALBENZA® tablets), 200 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. This medication is used to treat certain tapeworm infections (such as neurocysticercosis and hydatid disease).

The group also received a tentative approval for Pregabalin Capsules (US RLD – Lyrica) in the strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. Pregabalin is used to help control certain kinds of seizures, painful nerve diseases and fibromyalgia.

The group now has 239 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04.

**About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

***